Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade

SMi Group 4 - 5 February 2020, London, UK.
SMi presents Europe's leading 14th annual Parallel Trade conference, taking place in London. As the only B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The size of the EU market in pharmaceutical distribution is around €5bn, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn, while the annual export figure approximates £600m.

The 2020 event will hold a particular place of significance on shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights.

Furthermore, the FMD (Falsified Medicines Directive) will be coming into effect in February 2020. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market.

The benefits of attending

This conference is a must-attend show for anyone involved in the parallel trade industry within pharmaceuticals and life sciences. Attending the show gives you the chance to interact with and discuss common issues with leaders involved in all the areas of the parallel trade industry. Furthermore, this provides core information to further strengthen your industry knowledge and approaches.
  • Assessing the economic impact and dynamics of Parallel Trade
  • Reviewing how to overcome the challenges and hurdles in Parallel Trade
  • Understanding the underlying principles of the EU internal market and competition policies
  • Discussing the impact of Parallel trade on patient safety
  • What's the impact and consequences of a no deal Brexit on testing and clinical trials?
  • Impact on shortages, availability, accessibility and innovation
  • Assessing current EU legislative instruments and changes in IP framework
  • An update on current illegal trade cases and the Falsified Medicines Directive

Plus two pre-conference interactive workshops

Workshop A

Parallel Trade and Brexit... Where are we now?
Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd

Workshop B

Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade
John Schmidt, Partner, Antitrust, Arnold & Porter Kaye Scholer

For more information and to register, please visit:
http://www.parallel-trade.com/wpnwl

Early-Bird Rates

  • Register by 31st October to save £400
  • Register by 29th November to save £200
  • Register by 13th December to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Novartis and life sciences companies commit expert…

Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics...

Amgen and the Amgen Foundation commit up to $12.5 …

Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in...

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic. On March 19, 2020, Roche co...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

Consignment of 30 million hydroxychloroquine table…

Novartis announced that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Depar...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

FDA approves first plasma therapy for Houston Meth…

Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient i...

Experimental AI tool predicts which COVID-19 patie…

An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study ...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...